Why Zydus Life is in focus and why Bernstein sees nearly 30% upside
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Zydus Lifesciences shares are in focus on Wednesday, October 14, after two major USFDA updates.
- ✓The regulator issued five observations for the Moraiya plant following an inspection.
- ✓However, the USFDA also accepted a review for a Keytruda biosimilar.
Story at a Glance
- Category
- BUSINESS
- Reported By
- CNBC TV18
- Reading Speed
- 4 Minute(s)
- Market Focus
- India Economy
Shares of Zydus Lifesciences Ltd. are in focus on Wednesday, October 14, due to two announcements made by the company a day prior with regards to the US drug regulator.
While the US Food and Drug Administration (USFDA) issued five observations for Zydus Life's manufacturing facility in Moraiya, Ahmedabad, it also accepted to review the Biologics License Application (BLA) of a proposed biosimilar to Keytruda (pembrolizumab). Global investment banking firm Bernstein is positive regarding the latter.
Five observations for Zydus' Ahmedabad plant
Zydus Life informed the exchanges on Tuesday that the US Food and Drug Administration (USFDA) inspected the company's manufacturing plant at Moraiya, Ahmedabad from October 5 to October 13, 2026. The inspection closed with five observations, it said.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
CNBC TV18
Read the full, original unfiltered story directly on the publisher's portal.